LIU Xiaohua, XIAO Chunfang, LIU Linxiu. Clinical application of combined detection of serum NSE, CYFRA21-1, SCC and CEA in diagnosis of lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(19): 12-14. DOI: 10.7619/jcmp.202019004
Citation: LIU Xiaohua, XIAO Chunfang, LIU Linxiu. Clinical application of combined detection of serum NSE, CYFRA21-1, SCC and CEA in diagnosis of lung cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(19): 12-14. DOI: 10.7619/jcmp.202019004

Clinical application of combined detection of serum NSE, CYFRA21-1, SCC and CEA in diagnosis of lung cancer

More Information
  • Received Date: August 04, 2020
  • Objective To investigate the clinical application of combined detection of squamous cell carcinoma antigen(SCC), neuron-specific enolase(NSE), carcinoembryonic antigen(CEA)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)in diagnosis of lung cancer. Methods A total of 41 patients with lung cancer and 41 patients with benign tumor were separately selected as lung cancer group and benign group. Another 41 healthy people with physical examination were selected as healthy group. Serum CEA, NSE, SCC and CYFRA21-1 levels of three groups were compared. The specificity, sensitivity and accuracy of combined tests of four indicators and single test in diagnosis of lung cancer were analyzed. Results The serum NSE, SCC, CEA and CYFRA21-1 levels in the lung cancer group were significantly higher than those of the benign group and the healthy group(P<0.05); the NSE, SCC, CEA and CYFRA21-1 levels in the benign group and the healthy group showed no significant differences(P>0.05). The specificities of single detection and combined detection in diagnosis of lung cancer were both higher, but no significant differences were found(P>0.05). The sensitivity and accuracy of combined detection of NSE, SCC, CEA and CYFRA21-1 were 95.12% and 93.50% respectively, which were significantly higher than those of single detection(P<0.05). Conclusion Combined detection of NSE, SCC, CEA and CYFRA21-1 levels has higher accuracy and sensitivity in the diagnosis of lung cancer, which can effectively distinguish benign lung lesions from lung cancer, and it is of great value in clinical diagnosis.
  • 张颖, 董秀鹏, 杜静, 等. 肿瘤标志物CYFRA21-1、SCC、CEA、NSE、CA125检验在肺癌诊断中的价值[J]. 现代肿瘤医学, 2018, 26(11): 1701-1703.
    刘志华, 卢旭妹, 容亓. 血清标志物CYFRA21-1、SCC、NSE、CEA及ProGRP联合检测在非小细胞性肺癌中的诊断价值[J]. 河北医药, 2019, 41(10): 1464-1468.
    黄芳, 薛丽, 宋琳岚, 等. 胸水和血清CEA、CA125、CYFRA21-1、NSE和Pro-GRP联合检测对肺癌的诊断价值[J]. 现代肿瘤医学, 2018, 26(13): 2054-2058.
    南阳光, 周俊. CEA、CYFRA21-1、NSE、CA125联合检测在肺癌诊断中的应用效果[J]. 实用癌症杂志, 2018, 33(4): 527-529.
    戎荣, 程义壮, 沈佐君. 四种血清肿瘤标志物联合检测在肺癌诊断中的价值[J]. 山东医药, 2018, 58(1): 78-80.
    龚红娟, 蔡锦洪, 龚菊兰. 血清CYFRA21-1、CEA、NSE、CA199、CA125联合检测在肺癌诊断中的价值[J]. 贵州医药, 2019, 43(3): 450-453.
    翟永梅. 肺癌诊断中CEA、CYFRA21-1、NSE的联合检测运用探究[J]. 临床检验杂志: 电子版, 2019, 8(2): 58-59.
    沈菁, 李亚东, 郑庆祝, 等. 血清五种肿瘤标志物检测对肺癌早期诊断的价值[J]. 福建医科大学学报, 2019, 53(2): 111-115.
    徐文平, 刘继斌. 血清肿瘤标志物联合检测对肺癌的诊断价值观察上[J]. 贵州医药, 2019, 43(1): 131-133.
    谢朝辉, 方堃. 肿瘤标志物联合检测在肺癌诊断中的价值[J]. 中国医药导报, 2018, 15(25): 152-155.
    宋晓龙, 周建平, 雷艳君. 5种肿瘤标志物联合检测在肺癌诊断中的价值[J]. 检验医学与临床, 2019, 16(11): 1533-1536.
    牛安琳, 罗艳容, 刘功成, 等. 6种肿瘤标志物联合检测在辅助肺癌诊断及分型中的应用价值[J]. 中国卫生检验杂志, 2019, 29(10): 1235-1237

    , 1241.
    董芸, 袁峥玺, 姚原. 肿瘤标志物SCC-Ag、Cyf21-1、CEA、ProGRP、及NSE联合检测在肺癌诊断中的应用[J]. 中国实验诊断学, 2019, 23(3): 384-386.
    兰福全, 卢斌. 多种肿瘤标志物联合检测对肺癌诊断的临床价值[J]. 海南医学, 2018, 29(23): 3277-3279.
    俞欢欢, 刘玉薇, 万楠. 肿瘤标志物联合检测诊断肺癌的临床价值[J]. 中国实验诊断学, 2018, 22(11): 1928-1931.

Catalog

    Article views (975) PDF downloads (70) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return